onr:"swepub:oai:DiVA.org:uu-154914"
Search: onr:"swepub:oai:DiVA.org:uu-154914" > Risk of Bleeding Wi...
- 1 of 1
- Previous record
- Next record
- To hitlist
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
- Eikelboom, John W. (author)
-
- Wallentin, Lars, 1943- (author)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)
- Connolly, Stuart J. (author)
- show more...
- Ezekowitz, Mike (author)
- Healey, Jeff S. (author)
- Yang, Sean (author)
- Alings, Marco (author)
- Kaatz, Scott (author)
- Hohnloser, Stefan H. (author)
- Diener, Hans-Christoph (author)
- Franzosi, Maria Grazia (author)
- Huber, Kurt (author)
- Reilly, Paul (author)
- Varrone, Jeanne (author)
- Yusuf, Salim (author)
- show less...
- (creator_code:org_t)
- 2011
- 2011
- English.
- In: Circulation. - 0009-7322 .- 1524-4539. ; 123:21, s. 2363-2372
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Background-Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Methods and Results-The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. Compared with warfarin, dabigatran 110 mg twice a day was associated with a lower risk of major bleeding (2.87% versus 3.57%; P=0.002), whereas dabigatran 150 mg twice a day was associated with a similar risk of major bleeding (3.31% versus 3.57%; P=0.32). There was a significant treatment-by-age interaction, such that dabigatran 110 mg twice a day compared with warfarin was associated with a lower risk of major bleeding in patients aged = 75 years (4.43% versus 4.37%; P=0.89; P for interaction = 75 years (5.10% versus 4.37%; P=0.07; P for interaction = 75 years, intracranial bleeding risk is lower but extracranial bleeding risk is similar or higher with both doses of dabigatran compared with warfarin.
Keyword
- anticoagulants
- atrial fibrillation
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Eikelboom, John ...
- Wallentin, Lars, ...
- Connolly, Stuart ...
- Ezekowitz, Mike
- Healey, Jeff S.
- Oldgren, Jonas, ...
- show more...
- Yang, Sean
- Alings, Marco
- Kaatz, Scott
- Hohnloser, Stefa ...
- Diener, Hans-Chr ...
- Franzosi, Maria ...
- Huber, Kurt
- Reilly, Paul
- Varrone, Jeanne
- Yusuf, Salim
- show less...
- Articles in the publication
- Circulation
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
